Hypothalamic response to experimental allergic encephalomyelitis: role of substance P.
Adjuvant-induced arthritis (AA) is thought to be a model for experimental chronic stress that has as main features decreased adrenocorticotropin hormone (ACTH) plasma levels and a rise in median eminence content of arginine vasopressin (AVP) due to the activity of substance P. In experimental allergic encephalomyelitis (EAE), another chronic stress model, the role of substance P action is not clear. In this paper we tried to clarify the role of substance P in Lewis rats, which are susceptible to this disease. EAE was induced using myelin basic protein plus complete Freund's adjuvant injected into the hind limbs. One day later injections of an antagonist to substance P (RP 67580), saline, and substance P were administered daily for 12-14 days through a stainless steel cannula into the lateral ventricle of the brain, and then the rats were killed. The rats were divided into groups of controls, sham, diseased controls (no intracerebroventricular injections) and EAE (injected intracerebroventricularly). Plasma was used for the quantification of ACTH and corticosterone but not AVP which was assayed in hypothalamic median eminence extracts. In noninjected diseased rats the plasma levels of ACTH and corticosterone were significantly higher than in noninjected control rats, whereas the AVP concentrations in the median eminence were unchanged. The substance P antagonist did not affect the levels of these hormones in plasma or the median eminence. Substance P decreased the plasma levels of ACTH and corticosterone but did not increase the median eminence content of vasopressin. Administration of the antagonist 30 min before an equivalent dose of substance P increased the plasma levels of the two hormones, but did not change the content of AVP. Based on the lack of response to the antagonist RP 67580 we suggest that the substance P has different roles in EAE and AA at least in the later stages of EAE (after 11 days of immunization).
Ruocco
Heloisa H
HH
Departamento de Patologia Clínica, Núcleo de Medicina e Cirurgia Experimental, Faculdade de Ciências Médicas, Universidade Estadual de Campinas (UNICAMP), Campinas, Brasil.
Fernandes
Gilberto A
GA
Namer
Izzie J
IJ
Depaulis
Antoine
A
Levy
Salomon
S
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000818:Animals; D001127:Arginine Vasopressin / Q000097:blood; D001835:Body Weight; D002908:Chronic Disease; D003345:Corticosterone / Q000097:blood; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology* / Q000473:pathology; D007031:Hypothalamus / Q000187:drug effects* / Q000276:immunology*; D007211:Indoles; D054833:Isoindoles; D008297:Male; D008636:Mesencephalon / Q000473:pathology; D015213:Neuroimmunomodulation / Q000502:physiology; D064729:Neurokinin-1 Receptor Antagonists; D051381:Rats; D011917:Rats, Inbred Lew; D013312:Stress, Physiological / Q000276:immunology; D013373:Substance P / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology*
D007211:Indoles; D054833:Isoindoles; D064729:Neurokinin-1 Receptor Antagonists; D001127:Arginine Vasopressin; C071693:7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one; D013373:Substance P; D000324:Adrenocorticotropic Hormone; D003345:Corticosterone